2 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Yang Hong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
| Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study Stereotactic body radiotherapy (SBRT), Tislelizumab, Chemotherapy - Lung Cancer (NSCLC) | Phase 3 | Recruiting | Yang Hong | 360 | 2024-10-15 | 2025-05-29 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1)
Radiosurgery (2) · Carboplatin (1) · Drug Therapy (1) · Paclitaxel (1) · Pemetrexed (1) · sintilimab (1) · tislelizumab (1)
China (2)